Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 6.3% Higher - Time to Buy?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) shares were up 6.3% during mid-day trading on Monday . The stock traded as high as $20.67 and last traded at $20.53. Approximately 236,275 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 458,450 shares. The stock had previously closed at $19.31.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent research reports. Wedbush reiterated an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $37.17.

Kiniksa Pharmaceuticals Price Performance

The firm has a market cap of $1.47 billion, a P/E ratio of -144.35 and a beta of 0.31. The company's 50-day moving average is $21.05 and its two-hundred day moving average is $21.49.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same quarter in the prior year, the business posted $0.35 EPS. The business's revenue was up 46.9% on a year-over-year basis. On average, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $20.48, for a total value of $245,760.00. Following the transaction, the chief operating officer now owns 77,363 shares in the company, valued at $1,584,394.24. The trade was a 13.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark Ragosa sold 8,879 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the completion of the transaction, the chief financial officer now directly owns 23,382 shares of the company's stock, valued at $540,124.20. This trade represents a 27.52 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,766 shares of company stock valued at $2,002,135. Corporate insiders own 54.57% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KNSA. Braidwell LP boosted its holdings in shares of Kiniksa Pharmaceuticals by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after acquiring an additional 557,934 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the last quarter. Millennium Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 50.9% in the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after buying an additional 263,146 shares during the period. Dimensional Fund Advisors LP raised its holdings in Kiniksa Pharmaceuticals by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after buying an additional 29,300 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its position in Kiniksa Pharmaceuticals by 1.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock worth $15,141,000 after buying an additional 10,209 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.